-
Something wrong with this record ?
An anaplastic cardiac large cell lymphoma: a case report and analysis of cardiac involvement in newly diagnosed non-Hodgkin's lymphoma from the Czech Lymphoma Study Group (CLSG) database
Lobello Cosimo, Janikova Andrea, Kren Leos, Hermanová Markéta, Sprlakova-Puková Andrea, Krejci Jan, Pospisilova Sarka, Pospisilova Sarka, Hamouzova Michaela, Belada David, Prochazka Vit, Duras Juraj, Mocikova Heidi and Trneny Marek
Language English
Document type Research Support, Non-U.S. Gov't, Case Reports
Grant support
NV16-31092A
MZ0
CEP Register
Digital library NLK
Full text - Article
NLK
Free Medical Journals
from 2005
MedKnow Publications
from 2005
ProQuest Central
from 2008-01-01 to 2024-01-31
Open Access Digital Library
from 2005-01-01
Medline Complete (EBSCOhost)
from 2005-01-01
Health & Medicine (ProQuest)
from 2008-01-01 to 2024-01-31
Medknow Open Access Medical Journals
from 2005
- MeSH
- Lymphoma, Large-Cell, Anaplastic * complications MeSH
- Middle Aged MeSH
- Humans MeSH
- Heart Neoplasms complications MeSH
- Risk Factors MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Publication type
- Case Reports MeSH
- Research Support, Non-U.S. Gov't MeSH
We report a rare case of anaplastic large cell ALK+ lymphoma (ALCL) with initial asymptomatic cardiac involvement. A 59-year-old male with infiltration of the right ventricular wall underwent standard combined chemotherapy (CHOP) and achieved remission without significant cardiac impairment. Additionally, we report the actual incidence of cardiac lymphoma in newly diagnosed non-Hodgkin Lymphomas (NHLs). In total, 16 patients with cardiac lymphoma were found (0.1% NHLs) in the Czech Lymphoma Study Group database. DLBCL was the most frequent histology subtype (50%), and ALCL was identified in 12.5% of cases. At initial diagnosis, the median age was 55.5 (range 21-74) years and 59% were men. None of the 16 patients with cardiac involvement had isolated heart lymphoma. The response to first-line therapy was 79% in 14/16 evaluable patients. The median progression-free survival and overall survival were nearly the same – approximately 3.5 years (range; 0.05-16.7ys), while the median follow up was 4 years.
1st Department of Internal Medicine Cardiology University Hospital St Anne Brno Czech Republic
CEITEC Central European Institute of Technology Brno Masaryk University Brno Czech Republic
Department of Clinical Hematology Teaching Hospital Ostrava Ostrava Czech Republic
Department of Hematology University Hospital Olomouc Olomouc Czech Republic
Department of Radiology University Hospital Brno Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22008620
- 003
- CZ-PrNML
- 005
- 20240614144748.0
- 007
- ta
- 008
- 220329s2017 x f 000 0| g||
- 009
- AR
- 024 7_
- $a 10.14312/2052-4994.2017-13 $2 doi
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a x
- 100 1_
- $a Lobello, Cosimo $u CEITEC – Central European Institute of Technology Brno, Masaryk University, Brno, Czech Republic
- 245 13
- $a An anaplastic cardiac large cell lymphoma: a case report and analysis of cardiac involvement in newly diagnosed non-Hodgkin's lymphoma from the Czech Lymphoma Study Group (CLSG) database $c Lobello Cosimo, Janikova Andrea, Kren Leos, Hermanová Markéta, Sprlakova-Puková Andrea, Krejci Jan, Pospisilova Sarka, Pospisilova Sarka, Hamouzova Michaela, Belada David, Prochazka Vit, Duras Juraj, Mocikova Heidi and Trneny Marek
- 520 9_
- $a We report a rare case of anaplastic large cell ALK+ lymphoma (ALCL) with initial asymptomatic cardiac involvement. A 59-year-old male with infiltration of the right ventricular wall underwent standard combined chemotherapy (CHOP) and achieved remission without significant cardiac impairment. Additionally, we report the actual incidence of cardiac lymphoma in newly diagnosed non-Hodgkin Lymphomas (NHLs). In total, 16 patients with cardiac lymphoma were found (0.1% NHLs) in the Czech Lymphoma Study Group database. DLBCL was the most frequent histology subtype (50%), and ALCL was identified in 12.5% of cases. At initial diagnosis, the median age was 55.5 (range 21-74) years and 59% were men. None of the 16 patients with cardiac involvement had isolated heart lymphoma. The response to first-line therapy was 79% in 14/16 evaluable patients. The median progression-free survival and overall survival were nearly the same – approximately 3.5 years (range; 0.05-16.7ys), while the median follow up was 4 years.
- 650 17
- $a anaplastický velkobuněčný lymfom $x komplikace $7 D017728 $2 czmesh
- 650 _7
- $a nádory srdce $x komplikace $7 D006338 $2 czmesh
- 650 _7
- $a rizikové faktory $7 D012307 $2 czmesh
- 650 _7
- $a lidé $7 D006801 $2 czmesh
- 650 _7
- $a lidé středního věku $7 D008875 $2 czmesh
- 650 _7
- $a mužské pohlaví $7 D008297 $2 czmesh
- 655 _7
- $a práce podpořená grantem $7 D013485 $2 czmesh
- 655 _7
- $a kazuistiky $7 D002363 $2 czmesh
- 700 1_
- $a Janikova, Andrea $u Department of Internal Medicine – Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Kren, Leos $u Department of Pathology, University Hospital and Faculty of Medicine, Masaryk University Brno, Czech Republic
- 700 1_
- $a Hermanova, Marketa $u 1st Department of Pathological Anatomy University Hospital St Anne and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Sprlakova-Pukova, Andrea $u Department of Radiology, University Hospital Brno, Czech Republic
- 700 1_
- $a Krejci, Jan $u 1st Department of Internal Medicine-Cardiology, University Hospital St Anne, Brno, Czech Republic
- 700 1_
- $a Pospisilova, Sarka $u CEITEC – Central European Institute of Technology Brno, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine – Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Pytlik, Robert $u 1st Department of Medicine, First Medical Faculty, Charles University, and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Hamouzova, Michaela $u 1st Department of Medicine, First Medical Faculty, Charles University, and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Belada, David $u 4th Department of Internal medicine - Hematology, Charles University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic
- 700 1_
- $a Prochazka, Vit $u Department of Hematology, University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Duras, Juraj $u Department of Clinical Hematology, Teaching Hospital Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Mocikova, Heidi $u Internal Clinic of Haematology, University Hospital Kralovske Vinohrady, Prague, Charles University in Prague, 3rd Faculty of Medicine, Prague, Czech Republic
- 700 1_
- $a Trneny, Marek $u 1st Department of Medicine, First Medical Faculty, Charles University, and General University Hospital, Prague, Czech Republic
- 773 0_
- $t Journal of cancer research and therapeutics $x 0973-1482 $g Roč. 5, č. 10 (2017), s. 66-71 $w MED00165442
- 910 __
- $a ABA008 $y 0 $z 0
- 990 __
- $a 20220329135240 $b ABA008
- 991 __
- $a 20240614144747 $b ABA008
- 999 __
- $a kom $b bmc $g 1775146 $s 1159814
- BAS __
- $a 3
- BMC __
- $a 2017 $b 5 $c 10 $d 66-71 $x MED00165442 $i 0973-1482 $m Journal of cancer research and therapeutics
- GRA __
- $a NV16-31092A $p MZ0
- LZP __
- $c NLK120 $d 20240614 $a AZV-2019